AbL Diagnostics SA (PA:ABLD) — Market Cap & Net Worth
Market Cap & Net Worth: AbL Diagnostics SA (ABLD)
AbL Diagnostics SA (PA:ABLD) has a market capitalization of $38.57 Million (€32.99 Million) as of September 19, 2026. Listed on the PA stock exchange, this France-based company holds position #22958 globally and #355 in its home market, demonstrating a 1.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AbL Diagnostics SA's stock price €2.44 by its total outstanding shares 16069356 (16.07 Million). Also see how large is AbL Diagnostics SA's balance sheet for a full breakdown of the balance sheet.
AbL Diagnostics SA Market Cap History: 2015 to 2026
AbL Diagnostics SA's market capitalization history from 2015 to 2026. Data shows growth from $44.13 Million to $45.84 Million (0.35% CAGR). Also see cash flow conversion of AbL Diagnostics SA for how efficiently the company converts equity into cash flow.
Index Memberships
AbL Diagnostics SA is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Financials
FRFIN
|
$385.74 Billion | 0.01% | #26 of 31 |
Weight: AbL Diagnostics SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
AbL Diagnostics SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AbL Diagnostics SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check AbL Diagnostics SA stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
8.11x
AbL Diagnostics SA's market cap is 8.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
57.12x
AbL Diagnostics SA's market cap is 57.12 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $78.25 Million | $550.13K | -$499.00K | 142.23x | N/A |
| 2017 | $58.71 Million | $655.83K | -$25.10K | 89.52x | N/A |
| 2018 | $75.62 Million | $343.34K | -$455.00K | 220.24x | N/A |
| 2022 | $271.51 Million | $8.75 Million | $1.11 Million | 31.03x | 245.56x |
| 2023 | $182.23 Million | $5.61 Million | $54.36K | 32.47x | 3352.31x |
| 2024 | $46.22 Million | $5.33 Million | $285.17K | 8.67x | 162.06x |
| 2025 | $56.36 Million | $6.95 Million | $986.70K | 8.11x | 57.12x |
Competitor Companies of ABLD by Market Capitalization
Companies near AbL Diagnostics SA in the global market cap rankings as of September 19, 2026. Review tangible net worth ratio of AbL Diagnostics SA to assess the quality of the company's equity after excluding intangible assets.
Key companies related to AbL Diagnostics SA by market ranking:
- Veeva Systems Inc Class A (NYSE:VEEV): Ranked #737 globally with a market cap of $37.44 Billion USD.
- Pro Medicus Ltd (AU:PME): Ranked #1877 globally with a market cap of $12.53 Billion USD ( AU$17.71 Billion AUD).
- Tempus AI, Inc. Class A Common Stock (NASDAQ:TEM): Ranked #2076 globally with a market cap of $11.06 Billion USD.
- BrightSpring Health Services, Inc. Common Stock (NASDAQ:BTSG): Ranked #2153 globally with a market cap of $10.63 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #737 | Veeva Systems Inc Class A | NYSE:VEEV | $37.44 Billion | $260.21 |
| #1877 | Pro Medicus Ltd | AU:PME | $12.53 Billion | AU$169.57 |
| #2076 | Tempus AI, Inc. Class A Common Stock | NASDAQ:TEM | $11.06 Billion | $77.84 |
| #2153 | BrightSpring Health Services, Inc. Common Stock | NASDAQ:BTSG | $10.63 Billion | $56.78 |
AbL Diagnostics SA Historical Marketcap From 2015 to 2026
Between 2015 and today, AbL Diagnostics SA's market cap moved from $44.13 Million to $ 45.84 Million, with a yearly change of 0.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €45.84 Million | -18.67% |
| 2025 | €56.36 Million | +21.95% |
| 2024 | €46.22 Million | -74.64% |
| 2023 | €182.23 Million | -32.88% |
| 2022 | €271.51 Million | +627.14% |
| 2021 | €37.34 Million | +34.75% |
| 2020 | €27.71 Million | -62.66% |
| 2019 | €74.21 Million | -1.86% |
| 2018 | €75.62 Million | +28.80% |
| 2017 | €58.71 Million | -24.97% |
| 2016 | €78.25 Million | +77.32% |
| 2015 | €44.13 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of AbL Diagnostics SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.57 Million USD |
| MoneyControl | $38.57 Million USD |
| MarketWatch | $38.57 Million USD |
| marketcap.company | $38.57 Million USD |
| Reuters | $38.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more